Annabelle Singer's Innovative Alzheimer's Research: A Non-Invasive Approach
Annabelle Singer, an associate professor and biomedical engineer at Georgia Institute of Technology and Emory University, is spearheading research into novel methods for treating Alzheimer's disease. Her laboratory is dedicated to understanding neural activity patterns in the brain and pinpointing disruptions in Alzheimer's patients to develop targeted brain stimulation therapies.
Non-Invasive Sensory Stimulation
Singer's research explores a unique non-invasive sensory stimulation method. This involves flickering lights and sound delivered at 40 Hz through specialized goggles and headphones.
This innovative approach aims to decode memory function in Alzheimer's patients by examining how neural activity failures contribute to memory impairment.
Promising Preliminary Findings
Preclinical studies and a subsequent feasibility study have yielded encouraging results. They indicated that one hour of daily 40 Hz flickering lights and sound had the potential to slow cognitive decline and reduce volume loss in brain regions crucial for memory.
Singer emphasizes that the overarching goal is to slow the progression of cognitive decline, rather than to reverse existing memory impairment.
Large-Scale Phase 3 Clinical Trial Underway
Building on these findings, a Phase 3 double-blind clinical trial is currently underway, encompassing nearly 700 patients at 70 locations across the United States. This significant study is led by Cognito Therapeutics, a medtech company, with Singer serving as a scientific adviser.
The trial's primary objective is to determine if participants undergoing this stimulation experience slower or no decline in cognitive function compared to untreated individuals. Completion of the trial is anticipated later this year.
A Novel Approach Beyond Drug Therapies
Singer's research represents a significant departure from the primary focus of many pharmaceutical companies on drug therapies for Alzheimer's. She notes that these drug-based treatments can come with significant side effects and varying efficacy rates.
Her work specifically investigates how neurons electrically generate memory and how these patterns are altered in Alzheimer's patients. This approach contrasts with solely focusing on molecular-scale protein accumulation, offering a fresh perspective on intervention.
The Broader Landscape of Alzheimer's Treatment
The societal impact of Alzheimer's disease is profound; it currently affects over 7 million Americans aged 65 or older, a number projected to nearly double by 2060.
Recent FDA fast-tracked approvals for medications like lecanemab and donanemab have been met with skepticism. Concerns persist regarding their modest improvements versus the risks of life-threatening side effects such as brain swelling or bleeding. Furthermore, these new therapies carry substantial annual costs.
Collaborative Proof-of-Concept Study
James Lah, director of the Cognitive Neurology Program at Emory University, collaborated with Singer on an initial proof-of-concept study. This study involved 10 patients with mild cognitive impairment who underwent daily flickering light and sound therapy for eight weeks.
Findings from this initial study indicated beneficial effects on patients' spinal fluid and altered electrical connectivity patterns in their electroencephalograms (EEGs), providing essential groundwork for the extensive ongoing Phase 3 trial.
Understanding Mechanism and Safety
Singer's research is grounded in established scientific principles demonstrating that flickering lights can influence neural activity. Her team discovered that combining light and sound at 40 Hz could effectively reach the hippocampus, a critical brain region for memory.
In initial feasibility tests, the most common side effect reported was headaches. Importantly, in a separate test involving individuals with seizure disorders, the flickering lights were observed to decrease subclinical seizure activity rather than induce seizures, suggesting a favorable safety profile.